Pharmacokinetics of sildenafil and its metabolite, N-desmethylsildenafil, in rats with liver cirrhosis and diabetes mellitus, alone and in combination

References

• Ackerman DM, Leibman KC. (1977). Effect of experimental diabetes on drug metabolism in the rat. Drug Metab Dispos 5:405–410.
   PubMed Web of Science ®Google Scholar
• Ahn CY, Bae SK, Bae SH, Kim T, Jung YS, Kim YC, Lee MG, Shin WG. (2009). Pharmacokinetics of oltipraz in diabetic rats with liver cirrhosis. Br J Pharmacol 156:1019–1028.
   PubMed Web of Science ®Google Scholar
• Ahn CY, Bae SK, Jung YS, Lee I, Kim YC, Lee MG, Shin WG. (2008). Pharmacokinetic parameters of chlorzoxazone and its main metabolite, 6-hydroxychlorzoxazone, after intravenous and oral administration of chlorzoxazone to liver cirrhotic rats with diabetes mellitus. Drug Metab Dispos 36:1233–1241.
   PubMed Web of Science ®Google Scholar
• Bae SH, Bae SK, Lee MG. (2009). Effect of hepatic CYP inhibitors on the metabolism of sildenafil and formation of its metabolite, N-desmethylsildenafil, in rats in vitro and in vivo. J Pharm Pharmacol 61:1637–1642.
   Google Scholar
• Bae SK, Lee SJ, Lee JY, Lee Y, Lee I, Kim SG, Lee MG. (2004). Pharmacokinetic changes of oltipraz after intravenous and oral administration to rats with liver cirrhosis induced by dimethylnitrosamine. Int J Pharm 275:227–238.
   PubMedGoogle Scholar
• Barnett CR, Gibson GG, Wolf CR, Flatt PR, Ioannides C. (1990). Induction of cytochrome P450III and P450IV family proteins in streptozotocin-induced diabetes. Biochem J 268:765–769.
   PubMed Web of Science ®Google Scholar
• Boudinot FD, Jusko WJ. (1984). Fluid shifts and other factors affecting plasma protein binding of prednisolone by equilibrium dialysis. J Pharm Sci 73:774–780.
   PubMed Web of Science ®Google Scholar
• Bradford MM. (1976). A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72:248–254.
   PubMed Web of Science ®Google Scholar
• Chiou WL. (1978). Critical evaluation of the potential error in pharmacokinetic studies of using the linear trapezoidal rule method for the calculation of the area under the plasma level–time curve. J Pharmacokinet Biopharm 6:539–546.
   PubMedGoogle Scholar
• Choi YH, Lee DC, Lee I, Lee MG. (2008). Changes in metformin pharmacokinetics after intravenous and oral administration to rats with short-term and long-term diabetes induced by streptozotocin. J Pharm Sci 97:5363–5375.
   Google Scholar
• Duggleby RG. (1995). Analysis of enzyme progress curves by nonlinear regression. Meth Enzymol 249:61–90.
   PubMed Web of Science ®Google Scholar
• George J, Liddle C, Murray M, Byth K, Farrell GC. (1995). Pre-translational regulation of cytochrome P450 genes is responsible for disease-specific changes of individual P450 enzymes among patients with cirrhosis. Biochem Pharmacol 49:873–881.
   PubMed Web of Science ®Google Scholar
• George J, Rao KR, Stern R, Chandrakasan G. (2001). Dimethylnitrosamine-induced liver injury in rats: the early deposition of collagen. Toxicology 156:129–138.
   PubMed Web of Science ®Google Scholar
• Gibaldi M, Perrier D (Eds.). (1982). Pharmacokinetics (2nd ed.). New York: Marcel-Dekker.
   Google Scholar
• Goeting NL, Fleming JS, Gallagher P, Walmsely BH, Karran SJ. (1986). Alterations in liver blood flow and reticuloendothelial function in progressive cirrhosis in the rat. J Nucl Med 27:1751–1754.
   Google Scholar
• Horiike N, Abe M, Kumagi T, Hiasa Y, Akbar SM, Michitaka K, Onji M. (2005). The quantification of cytochrome P-450 (CYP 3A4) mRNA in the blood of patients with viral liver diseases. Clin Biochem 38:531–534.
   Google Scholar
• Ioannides C. (1996). Expression of cytochrome P450 protein in disease. In: Cytochrome P450. Metabolic and Toxicological Aspects (Chapter 12). Boca Raton, FL: CRC Press, pp. 301–327.
   Google Scholar
• Jézéquel AM, Mancini R, Rinaldesi ML, Macarri G, Venturini C, Orlandi F. (1987). A morphological study of the early stages of hepatic fibrosis induced by low doses of dimethylnitrosamine in the rat. J Hepatol 5:174–181.
   PubMed Web of Science ®Google Scholar
• Kang KW, Kim YG, Cho MK, Bae SK, Kim CW, Lee MG, Kim SG. (2002). Oltipraz regenerates cirrhotic liver through CCAAT/enhancer binding protein-mediated stellate cell inactivation. FASEB J 16:1988–1990.
   PubMedGoogle Scholar
• Kim SH, Choi YM, Lee MG. (1993). Pharmacokinetics and pharmacodynamics of furosemide in protein-calorie malnutrition. J Pharmacokinet Biopharm 21:1–17.
   PubMedGoogle Scholar
• Kim YC, Lee AK, Lee JH, Lee I, Lee DC, Kim SH, Kim SG, Lee MG. (2005). Pharmacokinetics of theophylline in diabetes mellitus rats: induction of CYP1A2 and CYP2E1 on 1,3-dimethyluric acid formation. Eur J Pharm Sci 26:114–123.
   PubMed Web of Science ®Google Scholar
• Kwon SY. (2003). [Prevalence and clinical significance of diabetes mellitus in patients with liver cirrhosis]. Taehan Kan Hakhoe Chi 9:205–211.
   Google Scholar
• Lee JH, Lee MG. (2008). Telithromycin pharmacokinetics in rat model of diabetes mellitus induced by alloxan or streptozotocin. Pharm Res 25:1915–1924.
   PubMed Web of Science ®Google Scholar
• Lee MG, Chiou WL. (1983). Evaluation of potential causes for the incomplete bioavailability of furosemide: gastric first-pass metabolism. J Pharmacokinet Biopharm 11:623–640.
   PubMedGoogle Scholar
• Matzke GR, Frye RF, Early JJ, Straka RJ, Carson SW. (2000). Evaluation of the influence of diabetes mellitus on antipyrine metabolism and CYP1A2 and CYP2D6 activity. Pharmacotherapy 20:182–190.
   PubMed Web of Science ®Google Scholar
• Mitruka BM, Rawnsley HM (Eds.). (1981). Clinical, Biochemical and Hematological Reference Values in Normal Experimental Animals and Normal Humans (2nd ed.). New York: Masson Publishing.
   Google Scholar
• Moscatiello S, Manini R, Marchesini G. (2007). Diabetes and liver disease: an ominous association. Nutr Metab Cardiovasc Dis 17:63–70.
   PubMed Web of Science ®Google Scholar
• Muirhead GJ, Wilner K, Colburn W, Haug-Pihale G, Rouviex B. (2002). The effects of age and renal and hepatic impairment on the pharmacokinetics of sildenafil. Br J Clin Pharmacol 53(Suppl. 1):21S–30S.
   Google Scholar
• Musicki B, Burnett AL. (2007). Endothelial dysfunction in diabetic erectile dysfunction. Int J Impot Res 19:129–138.
   PubMed Web of Science ®Google Scholar
• Nam BH, Sohn DH, Ko G, Kim JB. (1997). Effect of hepatic cirrhosis on the pharmacokinetics of theophylline in rats. Arch Pharm Res 20:318–323.
   Google Scholar
• Ohara K, Kusano M. (2002). Anti-transforming growth factor-beta1 antibody improves survival rate following partial hepatectomy in cirrhotic rats. Hepatol Res 24:174–183.
   Google Scholar
• Øie S, Guentert TW. (1982). Comparison of equilibrium time in dialysis experiments using spiked plasma or spiked buffer. J Pharm Sci 71:127–128.
   PubMed Web of Science ®Google Scholar
• Reinke LA, Stohs SJ, Rosenberg H. (1978). Altered activity of hepatic mixed-function mono-oxygenase enzymes in streptozotocin-induced diabetic rats. Xenobiotica 8:611–619.
   PubMed Web of Science ®Google Scholar
• Sato H, Terasaki T, Okumura K, Tsuji A. (1991). Effect of receptor up-regulation on insulin pharmacokinetics in streptozotocin-treated diabetic rats. Pharm Res 8:563–569.
   PubMed Web of Science ®Google Scholar
• Shim HJ, Lee EJ, Kim SH, Kim SH, Yoo M, Kwon JW, Kim WB, Lee MG. (2000). Factors influencing the protein binding of a new phosphodiesterase V inhibitor, DA-8159, using an equilibrium dialysis technique. Biopharm Drug Dispos 21:285–291.
   PubMedGoogle Scholar
• Shin HS, Bae SK, Lee MG. (2006). Pharmacokinetics of sildenafil after intravenous and oral administration in rats: hepatic and intestinal first-pass effects. Int J Pharm 320:64–70.
   PubMed Web of Science ®Google Scholar
• Sotaniemi EA, Pelkonen O, Arranto AJ, Tapanainen P, Rautio A, Pasanen M. (2002). Diabetes and elimination of antipyrine in man: an analysis of 298 patients classified by type of diabetes, age, sex, duration of disease and liver involvement. Pharmacol Toxicol 90:155–160.
   PubMedGoogle Scholar
• Thummel KE, Schenkman JB. (1990). Effects of testosterone and growth hormone treatment on hepatic microsomal P450 expression in the diabetic rat. Mol Pharmacol 37:119–129.
   PubMed Web of Science ®Google Scholar
• Toda K, Miwa Y, Kuriyama S, Fukushima H, Shiraki M, Murakami N, Shimazaki M, Ito Y, Nakamura T, Sugihara J, Tomita E, Nagata C, Suzuki K, Moriwaki H. (2005). Erectile dysfunction in patients with chronic viral liver disease: its relevance to protein malnutrition. J Gastroenterol 40:894–900.
   PubMed Web of Science ®Google Scholar
• Vidal J, Ferrer JP, Esmatjes E, Salmeron JM, González-Clemente JM, Gomis R, Rodés J. (1994). Diabetes mellitus in patients with liver cirrhosis. Diabetes Res Clin Pract 25:19–25.
   Google Scholar
• Walker DK, Ackland MJ, James GC, Muirhead GJ, Rance DJ, Wastall P, Wright PA. (1999). Pharmacokinetics and metabolism of sildenafil in mouse, rat, rabbit, dog and man. Xenobiotica 29:297–310.
   PubMed Web of Science ®Google Scholar
• Wang Y, Chow MS, Zuo Z. (2008). Mechanistic analysis of pH-dependent solubility and trans-membrane permeability of amphoteric compounds: application to sildenafil. Int J Pharm 352:217–224.
   PubMed Web of Science ®Google Scholar
• Wang Z, Hall SD, Maya JF, Li L, Asghar A, Gorski JC. (2003). Diabetes mellitus increases the in vivo activity of cytochrome P450 2E1 in humans. Br J Clin Pharmacol 55:77–85.
   PubMed Web of Science ®Google Scholar
• Wilkinson GR, Shand DG. (1975). A physiological approach to hepatic drug clearance. Clin Pharmacol Ther 18:377–390.
   PubMed Web of Science ®Google Scholar